0001103021-20-000081.txt : 20200512
0001103021-20-000081.hdr.sgml : 20200512
20200512184832
ACCESSION NUMBER: 0001103021-20-000081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200508
FILED AS OF DATE: 20200512
DATE AS OF CHANGE: 20200512
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sirgo Mark A
CENTRAL INDEX KEY: 0001301715
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31361
FILM NUMBER: 20870575
MAIL ADDRESS:
STREET 1: C/O BIODELIVERY SCIENCES INTERNATIONAL
STREET 2: 801 CORPORATE CENTER DRIVE -SUITE 210
CITY: RALEIGH
STATE: NC
ZIP: 27607
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC
CENTRAL INDEX KEY: 0001103021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 352089858
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
BUSINESS PHONE: 919 582 9050
MAIL ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
FORMER COMPANY:
FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP
DATE OF NAME CHANGE: 20000111
4
1
wf-form4_158932369364623.xml
FORM 4
X0306
4
2020-05-08
0
0001103021
BIODELIVERY SCIENCES INTERNATIONAL INC
BDSI
0001301715
Sirgo Mark A
C/O BIODELIVERY SCIENCES INTL, INC.,
4131 PARKLAKE AVENUE, SUITE 225
RALEIGH
NC
27612
1
0
0
0
Common Stock
2020-05-08
4
S
0
100000
5.07
D
1264595
D
Common Stock
2020-05-11
4
M
0
22500
0
A
1287095
D
Restricted Stock Units
0.0
2020-05-11
4
M
0
22500
0
D
2020-05-11
2020-05-11
Common Stock
22500.0
0
D
The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.
On May 8, 2020, the Reporting Person sold an aggregate of 100,000 shares of the Issuer's Common Stock at a weighted average price of $5.07 per share. The highest sale price for the Common Stock was $5.29 per share and the lowest sale price was $5.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended.
/s/ Mark A. Sirgo
2020-05-12